Testing rimegepant for migraine—time to revise the trial design? – Authors' reply

[...]Gasparini and colleagues' request for p values and stratified analyses is puzzling. PJG reports personal fees for consulting from Biohaven Pharmaceuticals during writing; grants and personal fees from Amgen and Eli Lilly; grants from Celgene; personal fees from Alder Biopharmaceuticals, Al...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2020-06, Vol.395 (10241), p.1901-1902
Main Authors: Croop, Robert, Goadsby, Peter J, Stock, David A, Lipton, Richard B
Format: Article
Language:English
Subjects:
Contraindications
Drugs
Headache
Magnetic fields
Migraine
Pharmaceutical industry
Pharmaceuticals
Psychometrics
Regulatory approval
Stock options
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]Gasparini and colleagues' request for p values and stratified analyses is puzzling. PJG reports personal fees for consulting from Biohaven Pharmaceuticals during writing; grants and personal fees from Amgen and Eli Lilly; grants from Celgene; personal fees from Alder Biopharmaceuticals, Allergan, Clexio, Electrocore LLC, eNeura, Impel Neuropharma, MundiPharma, Novartis, Teva Pharmaceuticals, and WL Gore; fees for publishing from Oxford University Press, Massachusetts Medical Society, Wolters Kluwer, and MedicoLegal work; fees for advice through Gerson Lehrman Group and Guidepoint; holds stock options in Trigemina, outside of writing; and a patent for magnetic stimulation for headache assigned to eNeura without fee. RBL reports personal fees from Acorda Therapeutics, Alder, Allergan, Amgen, Avanir Pharmaceuticals, Biohaven, CVS Health, Dr Reddy's Laboratories, Eli Lilly and Company, eNeura Therapeutics, Merck, Novartis, Sun Pharmaceutical Industries, Supernus Pharmaceuticals, Teva Pharmaceuticals USA, Vector psychometrics, Vedanta Research, outside of writing; receives royalties from Wolff's Headache seventh and eighth edition (Oxford Press University, 2009); and consults for and holds stock options in Biohaven Pharmaceuticals and eNeura.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(20)30231-2